DR. SURAJ S VENNA MD
Prescription History 1366433302
Dermatology in Fairfax, VA


Quality Rating: 81.28 out of 100 score

NPI Status: Active since October 31, 2005

Contact Information

8081 INNOVATION PARK DR
FAIRFAX, VA
ZIP 22031
Phone: (571) 472-4724
Fax: (571) 472-0241

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. SURAJ S VENNA MD, an active Dermatology specialist practicing in Fairfax, VA. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 16 documented patient claims. Among these therapy options, the most frequently utilized medication is Imiquimod, which accounts for 16 claims alone.

Medication Index

No matching medications currently found on file.

Imiquimod

Generic Formulation: ImiquimodSpecialty: Dermatology
Provider Metrics Summary
Total Claims 16
30-Day Fills 18.7
Days Supply 533
VA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills28.3
Peer Average Days Supply753
Conservative Utilization

This provider writes prescriptions for this formulation 30.4% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $536.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.54

State Avg Cost Per Claim

$45.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.

Therapeutic Applications

This medication is used to treat certain types of growths on the skin. These are precancerous growths (actinic keratoses), a certain type of skin cancer (superficial basal cell carcinoma), and warts on the outside of the genitals/anus. Treating these conditions can decrease complications from them. Imiquimod belongs to a group of drugs called immune response modifiers. It is believed to work by helping to activate your immune system to fight these abnormal skin growths. This product is not recommended for use on children under 12 years of age unless specifically directed by your doctor.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. SURAJ S VENNA MD provides transparency into local medical care patterns within Fairfax, VA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Dermatology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.